Celcuity Product Launch
Celcuity Inc. announced the commercial availability of REVTORPYK™ (gedatolisib) in the United States for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation. The therapy, which was FDA-approved in July 2026, is the first to inhibit all class I PI3K isoforms and mTOR complexes to blockade the PAM pathway. The company has also launched the REVTORPYK Support Services program to assist with patient access and financial assistance.